Svetlana Lucas
Director/Miembro de la Junta en ATYR PHARMA, INC. .
Fortuna: 9 570 $ al 30/04/2024
Perfil
Dr. Svetlana Lucas is an Independent Director at aTyr Pharma, Inc. and a Chief Business Officer at Scribe Therapeutics, Inc. She is on the Board of Directors at aTyr Pharma, Inc. Dr. Lucas was previously employed as a Senior Vice President-Business Development by Tizona Therapeutics, Inc. and a Head-Oncology & Inflammation by Amgen, Inc. She received her undergraduate degree from Moscow State University Lomonosov and a doctorate degree from California Institute of Technology.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ATYR PHARMA, INC.
0.01% | 01/03/2024 | 6 000 ( 0.01% ) | 9 570 $ | 30/04/2024 |
Cargos activos de Svetlana Lucas
| Empresas | Cargo | Inicio |
|---|---|---|
| ATYR PHARMA, INC. | Director/Miembro de la Junta | 28/06/2019 |
Scribe Therapeutics, Inc.
 Scribe Therapeutics, Inc. BiotechnologyHealth Technology Scribe Therapeutics, Inc. engages in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Berkeley, CA. | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Svetlana Lucas.
| Empresas | Cargo | Fin |
|---|---|---|
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/06/2019 |
| AMGEN INC. | Corporate Officer/Principal | 01/07/2015 |
Formación de Svetlana Lucas.
| California Institute of Technology | Doctorate Degree |
| Moscow State University Lomonosov | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ATYR PHARMA, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Health Technology |
Scribe Therapeutics, Inc.
Scribe Therapeutics, Inc. BiotechnologyHealth Technology Scribe Therapeutics, Inc. engages in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Berkeley, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Svetlana Lucas